The Evolving Role of Artificial Intelligence in Radiotherapy Treatment Planning-A Literature Review.

This paper examines the integration of artificial intelligence (AI) in radiotherapy for cancer treatment. The importance of radiotherapy in cancer management and its time-intensive planning process make AI adoption appealing especially with the escalating demand for radiotherapy. This review highlights the efficacy of AI across medical domains, where it surpasses human capabilities in areas such as cardiology and dermatology.

Somatostatin Receptor Imaging with [F]FET-βAG-TOCA PET/CT and [Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.

There is a clinical need for F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [F]fluoroethyl-triazole-[Tyr]-octreotate ([F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of [F]FET-βAG-TOCA PET/CT compared with [Ga]Ga-DOTA- peptide PET/CT in patients with NET.

Bench to Bedside Development of [F]Fluoromethyl-(1,2-H)choline ([F]D4-FCH).

Malignant transformation is characterised by aberrant phospholipid metabolism of cancers, associated with the upregulation of choline kinase alpha (CHKα). Due to the metabolic instability of choline radiotracers and the increasing use of late-imaging protocols, we developed a more stable choline radiotracer, [F]fluoromethyl-[1,2-H]choline ([F]D4-FCH). [F]D4-FCH has improved protection against choline oxidase, the key choline catabolic enzyme, via a H/D isotope effect, together with fluorine substitution.

Feasibility of [F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study.

Purpose: MRI and PET are used in neuro-oncology for the detection and characterisation of lesions for malignancy to target surgical biopsy and to plan surgical resections or stereotactic radiosurgery. The critical role of short-chain fatty acids (SCFAs) in brain tumour biology has come to the forefront. The non-metabolised SCFA radiotracer, [F]fluoropivalate (FPIA), shows low background signal in most tissues except eliminating organs and has appropriate human dosimetry.